Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

121-140 of 306 trials

Crohn's Disease: Obefazimod Study

We are testing a new medication, obefazimod, for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The study aims to see if it is more effective and safe compared to a placebo.

Crohn's Disease>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

Meningioma Treatment: Everolimus and 177Lu-DOTATATE

We are studying a new combination treatment for patients with grades 2 and 3 refractory meningioma. The goal is to see if this approach can help improve survival and manage tumor growth.

Malignant Meningiomas1-2 yearsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyOncology

Systemic Lupus Erythematosus: Ianalumab Study

We are evaluating a new medication, ianalumab, for patients with systemic lupus erythematosus to see if it helps improve symptoms and reduce flare-ups compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementRheumatology

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Allergic Rhinitis: New Immunotherapy for Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma1-2 yearsConfirmation phase (III)11-15 visits Investigational MedicinesAllergologyInternal Medicine

Head and Neck Cancer: Dostarlimab Treatment Study

We are studying whether dostarlimab can improve outcomes for adults with locally advanced head and neck cancer after initial treatment. Participants will receive either the new treatment or a placebo to compare effects.

Squamous Cell Carcinoma of the Head and Neck3-6 monthsConfirmation phase (III)11-15 visits Investigational Medicines Cost ReimbursementOncology

HIV and HBV Co-Infection: Antiviral Treatment Strategies

We are studying two treatment reduction strategies for patients co-infected with HIV-1 and HBV to see how safely they can manage their viral infections. The trial will also look at the impact on quality of life and any potential side effects.

Co-infection with HIV-1 and HBV>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesHepatologyInfectious Diseases

C3 Glomerulopathy and ICGN: OMS906 Study

We are testing a new drug called OMS906 in patients with C3 Glomerulopathy or Idiopathic Immune Complex-Mediated Glomerulonephritis. The study aims to evaluate the safety and early effects of this treatment on kidney function.

Immune Complex Glomerulonephritis6-12 monthsEfficacy phase (II)11-15 visits No Placebo Investigational MedicinesNephrology

Primary IgA Nephropathy: Long-Term Study of Iptacopan

We are evaluating the long-term safety and tolerability of iptacopan in adults with primary IgA nephropathy. This study follows participants who have completed an earlier trial to see how well the treatment works over time.

IgA Nephropathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNephrology

Staccato Alprazolam for Prolonged Seizures in Ages 12 and Up

We are studying the safety of Staccato Alprazolam for treating long seizures in children and adults. This trial will help us learn how well it works and its effects on lung health over time.

Prolonged Seizure>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurology

Diabetic Retinopathy: BI 764524 Treatment Study

We are testing whether the new treatment BI 764524 can improve eye health in people with diabetic retinopathy. The study will compare its effects to a placebo to see if it helps prevent serious vision problems.

Diabetic Retinopathy6-12 monthsEfficacy phase (II)11-15 visits Investigational MedicinesEndocrinologyOphthalmology

Targeted Anti-Cancer Drugs: DRUP Trial

We are studying how well existing targeted drugs work for patients with advanced cancers that have specific genetic markers. This trial aims to improve access to effective treatments and gather important data on their use.

Non-Hodgkin LymphomaAdvanced Solid TumorT-cell Prolymphocytic Leukemia3-6 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteNeurology

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Lupus Nephritis: LNP023 Treatment Study

We are studying the safety and effectiveness of LNP023 in adults with active lupus nephritis. The goal is to see if it helps improve kidney function compared to standard treatments.

Lupus Nephritis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational MedicinesNephrologyRheumatology

C3 Glomerulopathy: Iptacopan Study

We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.

C3 Glomerulopathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementInternal MedicineNephrology

Systemic Sclerosis-Related Lung Disease: Belimumab Study

We are investigating the long-term safety and effects of belimumab in adults with lung disease linked to systemic sclerosis. This study aims to see how the treatment impacts lung function and overall tolerability.

Lung Involvement in Systemic SclerosisBronchial Diseases>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementPulmonologyRheumatology

Colorectal Cancer: RO7198457 Treatment Study

We are comparing a new treatment called RO7198457 to watchful waiting in patients with high-risk, resected Stage II and Stage III colorectal cancer. The goal is to see if the new treatment can help prevent cancer recurrence better than simply monitoring.

Stage II/Stage III Rectal Cancer or Stage II (High Risk)/Stage III Colon Cancer>2 yearsEfficacy phase (II)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteOncology

Dostarlimab for Untreated Locally Advanced Rectal Cancer

We are studying the effects of dostarlimab in patients with untreated Stage II/III dMMR/MSI-H rectal cancer. The goal is to see how well it works and how safe it is for these individuals.

Rectal CancerEfficacy phase (II)11-15 visits No Placebo Investigational Medicines Partially RemoteGastroenterologyOncology

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Search Clinical Trials in the European Union